Pandemic Puts A Spotlight On Counterfeit Drugs
Is On-Dose Authentication The Answer?
As the ongoing COVID-19 pandemic forces health care to go digital, opportunities for fraud have proliferated. In Vivo explores the risks, the steps regulators are taking and how companies are looking to provide innovative solutions to help secure manufacturing supply chains.
You may also be interested in...
A selection of articles you might have missed from April 2021, including exclusive interviews with industry leaders and a deeper dive into drug development and R&D.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
In an exclusive interview, Alchemab CEO Alex Leech talks to In Vivo about the company’s method of identifying naturally occurring antibodies to target high unmet needs in oncology, neurodegeneration and infectious diseases.